[89Zr]-DFO-scFv-PEG-Cy5-C' dots

N/A

Report date: 2025/01/26 19:21:11

Base Information

Drug Name[89Zr]-DFO-scFv-PEG-Cy5-C' dots
Drug Alias Nameanti-HER2 89Zr-antibody fragment-nanoparticle conjugate (MedImmune/Memorial Sloan Kettering Cancer Center/Cornell University)Zirconium-labeled nanoparticle-drug conjugate (MedImmune/Memorial Sloan Kettering Cancer Center/Cornell University)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentRadiation-emitting products
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterMedimmune LlcCornell University
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A